Implications of PET Based Molecular Imaging on the Current and Future Practice of Medicine

Seminars in Nuclear Medicine

Volumn 34, Issue 1, 2004, Pages 56-69

  Alavi, Abass ^a   Kung, Justin W ^a   Zhuang, Hongming ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 NITROIMIDAZOL 1H YL) N (3 FLUOROPROPYL)ACETAMIDE; 3' FLUOROTHYMIDINE; AMINO ACID; ANTIBODY; ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CD22 ANTIGEN; CHOLINE; COPPER; COPPER 60; CYTOTOXIC AGENT; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE); ESTROGEN DERIVATIVE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; HORMONE; IODINE 124; IODINE 131; METHIONINE C 11; THIOSEMICARBAZONE; TRACER; UNCLASSIFIED DRUG; YTTRIUM; YTTRIUM 86; YTTRIUM 90;

ANGIOGENESIS; BONE DISEASE; CANCER; CANCER DIAGNOSIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HUMAN; HYPOXIA; IMAGING SYSTEM; INFECTION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL PRACTICE; MINIMALLY INVASIVE CARDIAC SURGERY; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; REVIEW;

EID: 0347357747     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2003.09.007     Document Type: Article

References (143)

1. Schaner EG, Chang AE, Doppman JL, et al: Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: A prospective radiologic-pathologic study. AJR Am J Roentgenol 131:51-54, 1978
2. Vanel D, Henry-Amar M, Lumbroso J, et al: Pulmonary evaluation of patients with osteosarcoma: Roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy. AJR Am J Roentgenol 143:519-523, 1984
3. Muhm JR, Brown LR, Crowe JK, et al: Comparison of whole lung tomography and computed tomography for detecting pulmonary nodules. AJR Am J Roentgenol 131:981-984, 1978
4. Crim JR, Cracchiolo A, Bassett LW, et al: Magnetic resonance imaging of the hindfoot. Foot & Ankle 10:1-7, 1989
5. Hilpert PL, Friedman AC, Radecki PD, et al: MRI of hemorrhagic renal cysts in polycystic kidney disease. AJR Am J Roentgenol 146:1167-1172, 1986
6. Semelka RC, Bagley AS, Brown ED, et al: Solitary hepatic metastasis: Comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breath-hold T1-weighted FLASH, and dynamic gadolinium-enhanced FLASH sequences. J Magn Reson Imaging 4:319-323, 1994
7. Stark DD, Wittenberg J, Butch RJ, et al: Hepatic metastases: Randomized, controlled comparison of detection with MR imaging and CT. Radiology 165:399-406, 1987
8. Czernin J, Phelps ME: Positron emission tomography scanning: Current and future applications. Annu Rev Med 53:89-112, 2002
9. Calautti C, Baron JC: Functional neuroimaging studies of motor recovery after stroke in adults: a review. Stroke 34:1553-1566, 2003
10. Grenier N, Basseau F, Ries M, et al: Functional MRI of the kidney. Abdom Imaging 28:164-175, 2003
11. Ntziachristos V, Chance B: Probing physiology and molecular function using optical imaging: Applications to breast cancer. Breast Cancer Res 3:41-46, 2001
12. Ntziachristos V, Bremer C, Weissleder R: Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 13:195-208, 2003
13. Dearling JL, Lewis JS, Mullen GE, et al: Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 25:788-792, 1998
14. Alavi A, Reivich M: The conception of FDG-PET imaging. Semin Nucl Med 32:2-5, 2002 (editorial)
15. Alavi A, Hirsch LJ: Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography: Evolution over the past 2 decades. Semin Nucl Med 21:58-81, 1991
16. Gambhir SS, Barrio JR, Herschman HR, et al: Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 26:481-490, 1999
17. Cherry SR: Fundamentals of positron emission tomography and applications in preclinical drug development. J Clin Pharmacol 41:482-491, 2001
18. Vaalburg W, Hendrikse NH, de Vries EF: Drug development, radiolabelled drugs and PET. Ann Med 31:432-437, 1999
19. Newberg A, Alavi A, Reivich M: Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Semin Nucl Med 32:13-34, 2002
20. Engel J Jr, Kuhl DE, Phelps ME, et al: Local cerebral metabolism during partial seizures. Neurology 33:400-413, 1983
21. Theodore WH, Newmark ME, Sato S, et al: [18F]fluorodeoxyglucose positron emission tomography in refractory complex partial seizures. Ann Neurol 14:429-437, 1983
22. Barrington SF, Koutroumanidis M, Agathonikou A, et al: Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia 39:753-766, 1998
23. Moran NF, Lemieux L, Kitchen ND, et al: Extrahippocampal temporal lobe atrophy in temporal lobe epilepsy and mesial temporal sclerosis. Brain 124:167-175, 2001
24. Kobayashi E, D'Agostino MD, Lopes-Cendes I, et al: Hippocampal atrophy and T2-weighted signal changes in familial mesial temporal lobe epilepsy. Neurology 60:405-409, 2003
25. Meyer PT, Cortes-Blanco A, Pourdehnad M, et al: Inter-modality comparisons of seizure focus lateralization in complex partial seizures. Eur J Nucl Med 28:1529-1540, 2001
26. Imbimbo BP, Martelli P, Troetel WM, et al: Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology 52:700-708, 1999
27. Morris JC, Cyrus PA, Orazem J, et al: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 50:1222-1230, 1998
28. Knapp MJ, Knopman DS, Solomon PR, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 271:985-991, 1994
29. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50:136-145, 1998
30. Rosler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. [erratum appears in BMJ 322:1456, 2001]. BMJ 318:633-638, 1999
31. Rosler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. [erratum appears in BMJ 322:1456, 2001]. BMJ 318:633-638, 1999
32. Kuhl DE, Metter EJ, Riege WH: Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Ann Neurol 15:419-424, 1984
33. Ishii K: Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 16:515-525, 2002
34. Alavi A, Dann R, Chawluk J, et al: Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med 16:2-34, 1986
35. Salmon E, Sadzot B, Maquet P, et al: Differential diagnosis of Alzheimer's disease with PET. J Nucl Med 35:391-398, 1994
36. Van Heertum RL, Tikofsky RS: Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med 33:77-85, 2003
37. Alavi A, Clark C, Fazekas F: Cerebral ischemia and Alzheimer's disease: Critical role of PET and implications for therapeutic intervention. J Nucl Med 39:1363-1365, 1998
38. Alavi A, Newberg AB, Souder E, et al: Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: Atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 34:1681-1687, 1993
39. Davis MR, Votaw JR, Bremner JD, et al: Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med 44:855-861, 2003
40. Vingerhoets FJ, Schulzer M, Ruth TJ, et al: Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease. J Nucl Med 37:421-426, 1996
41. Huang WS, Chiang YH, Lin JC, et al: Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients. J Nucl Med 44:999-1005, 2003
42. Alavi A, Newberg AB: AMetabolic consequences of acute brain trauma: is there a role for PET? J Nucl Med 37:1170-1172, 1996
43. Newberg AB, Alavi A: Neuroimaging in patients with head injury. Semin Nucl Med 33:136-147, 2003
44. Newberg A, Cotter A, Udeshi M, et al: A metabolic imaging severity rating scale for the assessment of cognitive impairment. Clin Nucl Med 28:565-570, 2003
45. Silverman DH, Small GW, Chang CY, et al: Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286:2120-2127, 2001
46. Mazziotta JC, Phelps ME, Pahl JJ, et al: Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 316:357-362, 1987
47. Kuhl DE, Phelps ME, Markham CH, et al: Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol 12:425-434, 1982
48. Kuwert T, Lange HW, Langen KJ, et al: Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease. Psychiatry Res 29:361-362, 1989
49. Hustinx R, Benard F, Alavi A: Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32:35-46, 2002
50. Wahl RL, Hawkins RA, Larson SM, et al: Proceedings of a National Cancer Institute workshop: PET in oncology-A clinical research agenda. Radiology 193:604-606, 1994
51. Rigo P, Paulus P, Kaschten BJ, et al: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23:1641-1674, 1996
52. Bar-Shalom R, Valdivia AY, Blaufox MD: PET imaging in oncology. Semin Nucl Med 30:150-185, 2000
53. Bury T, Dowlati A, Paulus P, et al: Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 23:204-206, 1996
54. Albes JM, Lietzenmayer R, Schott U, et al: Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg 47:42-47, 1999
55. Coleman RE: PET in lung cancer. J Nucl Med 40:814-820, 1999
56. Wahl RL: Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol 36:250-260, 2001
57. Zhuang H, Sinha P, Pourdehnad M, et al: The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 21:793-798, 2000
58. Bohuslavizki KH, Kluttman S, Sonnemann U, et al: [F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region]. Laryngorhinootologie 78:445-449, 1999
59. Bohuslavizki KH, Kluttman S, Kroger S, et al: FDG PET detection of unknown primary tumors. J Nucl Med 41:816-822, 2000
60. Braams JW, Pruim J, Kole AC, et al: Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 26:112-115, 1997
61. Lassen U, Daugaard G, Eigtved A, et al: 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 35:1076-1082, 1999
62. Kole AC, Nieweg OE, Pruim J, et al: Detection of unknown occult primary tumors using positron emission tomography. Cancer 82:1160-1166, 1998
63. Hustinx R, Smith RJ, Benard F, et al: Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26:1345-1348, 1999
64. Keyes JW Jr, Watson NE Jr, Williams DW 3rd, et al: FDG PET in head and neck cancer. AJR Am J Roentgenol 169:1663-1669, 1997
65. Weihrauch MR, Re D, Bischoff S, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 81:20-25, 2002
66. Delbeke D, Vitola JV, Sandler MP, et al: Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 38:1196-1201, 1997
67. Flamen P, Hoekstra OS, Homans F, et al: Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET). Eur J Cancer 37:862-869, 2001
68. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al: Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 227:319-323, 1998
69. Ruhlmann J, Schomburg A, Bender H, et al: Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 40:1195-1204, 1997
70. Valk PE, Abella-Columna E, Haseman MK, et al: Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 134:503-511, 1999
71. Moertel CG, Fleming TR, Macdonald JS, et al: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270:943-947, 1993
72. Vitola JV, Delbeke D, Sandler MP, et al: Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 171:21-26, 1996
73. Romer W, Hanauske AR, Ziegler S, et al: Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471, 1998
74. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
75. Stumpe KD, Urbinelli M, Steinert HC, et al: Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 25:721-728, 1998
76. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
77. Findlay M, Young H, Cunningham D, et al: Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 14:700-708, 1996
78. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
79. Zhuang H, Alavi A: 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32:47-59, 2002
80. Zhuang H, Duarte PS, Pourdehnad M, et al: The promising role of 18F-FDG PET in detecting infected lower limb prosthesis implants. J Nucl Med 42:44-48, 2001
81. Manthey N, Reinhard P, Moog F, et al: The use of [18 F] fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl Med Commun 23:645-653, 2002
82. Vanquickenborne B, Maes A, Nuyts J, et al: The value of (18)FDG-PET for the detection of infected hip prosthesis. Eur J Nucl Med Mol Imaging 30:705-715, 2003
83. Zhuang H, Duart PS, Pourdehand M, et al: Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med 25:281-284, 2000
84. Guhlmann A, Brecht-Krauss D, Suger G, et al: Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med 39:2145-2152, 1998
85. Blockmans D, Knockaert D, Maes A, et al: Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 32:191-196, 2001
86. Meller J, Altenvoerde G, Munzel U, et al: Fever of unknown origin: prospective comparison of [18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med 27:1617-1625, 2000
87. Lorenzen J, Buchert R, Bohuslavizki KH: Value of FDG PET in patients with fever of unknown origin. Nucl Med Commun 22:779-783, 2001
88. Neurath MF, Vehling D, Schunk K, et al: Noninvasive assessment of Crohn's disease activity: A comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97:1978-1985, 2002
89. Alavi A, Buchpiguel CA, Loessner A: Is there a role for FDG PET imaging in the management of patients with sarcoidosis? J Nucl Med 35:1650-1652, 1994
90. Lewis PJ, Salama A: Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 35:1647-1649, 1994
91. Ludwig V, Fordice S, Lamar R, et al: Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy. Clin Nucl Med 28:176-179, 2003
92. Yasuda S, Shohtsu A, Ide M, et al: High fluorine-18 labeled deoxyglucose uptake in sarcoidosis. Clin Nucl Med 21:983-984, 1996
93. Polisson RP, Schoenberg OI, Fischman A, et al: Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 38:819-825, 1995
94. Hara M, Goodman PC, Leder RA: FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr 23:16-18, 1999
95. Derdelinckx I, Maes A, Bogaert J, et al: Positron emission tomography scan in the diagnosis and follow-up of aortitis of the thoracic aorta. Acta Cardiol 55:193-195, 2000
96. Blockmans D, Maes A, Stroobants S, et al: New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 38:444-447, 1999
97. Yoshida K, Mullani N, Gould KL: Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 37:1701-1712, 1996
98. deKemp RA, Ruddy TD, Hewitt T, et al: Detection of serial changes in absolute myocardial perfusion with 82Rb PET. J Nucl Med 41:1426-1435, 2000
99. Yun M, Jang S, Cucchiara A, et al: 18F FDG uptake in the large arteries: A correlation study with the atherogenic risk factors. Semin Nucl Med 32:70-76, 2002
100. Vallabhajosula S, Machac J, Knesaurek K, et al: Imaging atherosclerotic macrophage density by positron emission tomography using F-18-fluorodeoxyglucose. J Nucl Med 37:38, 1996 (abstr)
101. Blake GM, Park-Holohan SJ, Cook GJ, et al: Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 31:28-49, 2001
102. van Eijkeren ME, Thierens H, Seuntjens J, et al: Kinetics of [methyl-11C]thymidine in patients with squamous cell carcinoma of the head and neck. Acta Oncol 35:737-741, 1996
103. Vander Borght T, Labar D, Pauwels S, et al: Production of [2-11C]thymidine for quantification of cellular proliferation with PET. Int J Rad Appl Instrum [A] 42:103-104, 1991
104. Barthel H, Cleij MC, Collingridge DR, et al: 3′-deoxy-3′ -[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63:3791-3798, 2003
105. Buck AK, Schirrmeister H, Hetzel M, et al: 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 62:3331-3334, 2002
106. Wagner M, Seitz U, Buck A, et al: 3′-[18F]fluoro-3′ -deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 63:2681-2687, 2003
107. Shields AF, Grierson JR, Dohmen BM, et al: Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336, 1998
108. Koh WJ, Bergman KS, Rasey JS, et al: Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33:391-398, 1995
109. Nunn A, Linder K, Strauss HW: Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 22:265-280, 1995
110. Fujibayashi Y, Taniuchi H, Yonekura Y, et al: Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38:1155-1160, 1997
111. Evans SM, Kachur AV, Shiue CY, et al: Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 41:327-336, 2000
112. Dolbier WR Jr, Li AR, Koch CJ, et al: [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 54:73-80, 2001
113. Blankenberg FG, Strauss HW: Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 16:352-361, 2002
114. Eliceiri BP, Cheresh DA: The role of alpha-v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103:1227-1230, 1999
115. Cheresh DA: Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metastasis Rev 10:3-10, 1991
116. Haubner R, Wester HJ, Weber WA, et al: Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785, 2001
117. Haubner R, Wester HJ, Burkhart F, et al: Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42:326-336, 2001
118. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001
119. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
120. Anderson CJ, Connett JM, Schwarz SW, et al: Copper-64-labeled antibodies for PET imaging. J Nucl Med 33:1685-1691, 1992
121. Henze M, Schuhmacher J, Hipp P, et al: PET imaging of somatostatin receptors using. J Nucl Med 42:1053-1056, 2001
122. Ogawa T, Shishido F, Kanno I, et al: Cerebral glioma: Evaluation with methionine PET. Radiology 186:45-53, 1993
123. Jager PL, Vaalburg W, Pruim J, et al: Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med 42:432-445, 2001
124. Hara T, Kosaka N, Kishi H: PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990-995, 1998
125. Kotzerke J, Prang J, Neumaier B, et al: Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27:1415-1419, 2000
126. Price DT, Coleman RE, Liao RP, et al: Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168:273-280, 2002
127. Dimitrakopoulou-Strauss A, Strauss LG: PET imaging of prostate cancer with 11C-acetate. J Nucl Med 44:556-558, 2003
128. Oyama N, Akino H, Kanamura H, et al: 11C-acetate PET imaging of prostate cancer. J Nucl Med 43:181-186, 2002
129. Mortimer JE, Dehdashti F, Siegel BA, et al: Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2:933-939, 1996
130. Dehdashti F, Mortimer JE, Siegel BA, et al: Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36:1766-1774, 1995
131. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683-693, 2002
132. Lin EC, Quaife RA: FDG uptake in chronic superior vena cava thrombus on positron emission tomographic imaging. Clin Nucl Med 26:241-242, 2001
133. Chang KJ, Zhuang H, Alavi A: Detection of chronic recurrent lower extremity deep venous thrombosis on fluorine-18 fluorodeoxyglucose positron emission tomography. Clin Nucl Med 25:838-839, 2000
134. Zhuang H, Pourdehnad M, Lambright ES, et al: Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412-1417, 2001
135. Matthies A, Hickeson M, Cuchiara A, et al: Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871-875, 2002
136. Suzuki S, Toyota T, Suzuki H, et al: Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and supposses glucose-6-phosphatase. Arch Biochem Biophys 235:418-426, 1984
137. Nelson CA, Wang JQ, Leav I, et al: The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 23:533-541, 1996
138. Gallagher BM, Fowler JS, Gutterson NI, et al: Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19:1154-1161, 1978
139. Townsend DW, Cherry SR: Combining anatomy and function: The path to true image fusion. Eur Radiol 11:1968-1974, 2001
140. Townsend DW: A combined PET/CT scanner: The choices. J Nucl Med 42:533-534, 2001
141. Cohade C, Osman M, Marshall LN, et al: PET-CT: Accuracy of PET and CT spatial registration of lung lesions. Eur J Nucl Med Mol Imaging 30:721-726, 2003
142. Costa DC, Visvikis D, Crosdale I, et al: Positron emission and computed X-ray tomography: A coming together. Nucl Med Commun 24:351-358, 2003
143. Lardinois D, Weder W, Hany TF, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003